Lung cancer individualized treatment gene testing platform:

The platform features a talent team of 3 with MD degree, 1 with master's degree, 1 of National Natural Science Foundation of China Outstanding Youth Fund recipient, and 6 technicians. The platform completes nearly 6,000 cases of molecular typing of tumor-driven genes annually, and has established a specimen bank covering tumor tissues, normal control tissues and blood samples; it has created a platform for precision treatment of lung cancer that meets clinical needs and scientific research value.

Blood drug concentration monitoring platform after lung transplantation:

The blood concentration testing platform has completed more than 3,200 tests of tacrolimus blood concentration and more than 1,000 tests of mycophenolic acid blood concentration in lung transplantation patients, assisting the clinic in guiding patients to individualized medication.

Lung transplantation has become the only effective treatment for many kinds of end-stage lung diseases, and is also recognized as an important means to improve the quality of survival and prolong the life span of patients with end-stage lung diseases. However, lung transplant recipients need to take immunosuppressants such as tacrolimus and mycophenolate mofetil for a long period of time to prevent and treat rejection reactions after surgery.

Tacrolimus has a narrow therapeutic concentration range, high toxicity, and significant dose-dependent toxicity and blood concentration. In different transplant populations, studies have also found large differences in pharmacokinetics between tacrolimus and mycophenolate mofetil individuals, and that in vivo and ex vivo factors affect their pharmacokinetics. Therefore, when tacrolimus and mycophenolate mofetil are applied clinically, in order to obtain the best immunosuppressive effect and reduce adverse effects, their blood concentrations need to be monitored, so that the dosage can be adjusted in a timely manner to guide the individualized clinical medication.

Inter-lab Quality Assessment:

Genetic testing inter-lab quality assessment obtained full score of European Molecular Genetics Quality Network inter-lab (EMQN)

The inter-lab quality assessment of gene testing has obtained a passing score in the inter-lab quality assessment of the Ministry of Health Clinical Inspection Center.

The inter-lab quality assessment of blood drug concentration monitoring (FK506) received a passing score in the inter-lab quality assessment of the Ministry of Health Pro-Test Center.

Fund Application:

Patent Application:

Invention Patent Grant No. (first inventor): 6636066 (Japan)

Invention Patent Application No. (First Applicant): 201810721654.1; 201910764107.6; 15854645; EP172109924.1

Bispecific Antibody Development (YY0411):

YY0411 is the world's first bispecific antibody targeting both HER2 and VEGF

International award-winning:

Article Publication:

More than 30 articles published with the highest impact factor of 25.805 and 10 articles with >10 points.